Marginal Biotin Deficiency During Normal Pregnancy
Overview
Authors
Affiliations
Background: Biotin deficiency is teratogenic in several mammalian species. Approximately 50% of pregnant women have an abnormally increased urinary excretion of 3-hydroxyisovaleric acid (3-HIA), which probably reflects decreased activity of the biotin-dependent enzyme methylcrotonyl-CoA carboxylase. However, increased 3-HIA excretion could result from pregnancy per se (eg, from an effect of pregnancy on renal handling of organic acids).
Objective: We tested the hypothesis that biotin supplementation significantly decreases 3-HIA excretion in pregnant women with abnormally increased 3-HIA excretion.
Design: Twenty-six pregnant women with increased 3-HIA excretion were studied in a randomized, placebo-controlled trial; 10 women were studied during early pregnancy (6-17 wk gestation) and 16 women during late pregnancy (21-37 wk gestation). Urine samples were collected before and after 14 d of supplementation with 300 microg (1.2 micromol) biotin/d or placebo.
Results: In the early-pregnancy group, 3-HIA excretion decreased (P < 0.006) by 11.7 +/- 3.6 mmol/mol creatinine (mean +/- SEM) in the 5 women who received biotin supplements, whereas 3-HIA excretion increased by 1.6 +/- 0.6 mmol/mol creatinine in the 5 women who received placebo. In the late-pregnancy group, 3-HIA excretion decreased (P < 0.002) by 7.1 +/- 1.2 mmol/mol creatinine in the 8 women who received biotin supplements, whereas 3-HIA excretion increased by 0.9 +/- 1.8 mmol/mol creatinine in the 8 women who received placebo.
Conclusions: This study provides evidence that the increased excretion of 3-HIA seen frequently in normal pregnancy reflects reduced biotin status. The conclusion that marginal biotin deficiency occurs frequently in the first trimester further raises concern about potential human teratogenicity.
Biotin Homeostasis and Human Disorders: Recent Findings and Perspectives.
Karachaliou C, Livaniou E Int J Mol Sci. 2024; 25(12).
PMID: 38928282 PMC: 11203980. DOI: 10.3390/ijms25126578.
Ma G, Yan H, Tye K, Tang X, Luo H, Li Z Microbiol Spectr. 2024; 12(6):e0041324.
PMID: 38687069 PMC: 11237737. DOI: 10.1128/spectrum.00413-24.
Adams J, Kirby J, Sorensen J, Pollard E, Audhya T Matern Health Neonatol Perinatol. 2022; 8(1):4.
PMID: 35818085 PMC: 9275129. DOI: 10.1186/s40748-022-00139-9.
Antibodies against biotin-labeled red blood cells can shorten posttransfusion survival.
Mock D, Stowell S, Franco R, Kyosseva S, Nalbant D, Schmidt R Transfusion. 2022; 62(4):770-782.
PMID: 35274303 PMC: 9007277. DOI: 10.1111/trf.16849.
Revised D-A-CH reference values for the intake of biotin.
Jungert A, Ellinger S, Watzl B, Richter M Eur J Nutr. 2022; 61(4):1779-1787.
PMID: 34977958 PMC: 9106636. DOI: 10.1007/s00394-021-02756-0.